

Innovation all for the patients



Roche A member of the Roche group

Roche Announces Results of EMPACTA Study for Chugai's Actemra for the Treatment of COVID-19

TOKYO, September 18, 2020 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release today regarding results of EMPACTA study for Actemra[®]/RoActemra[®] [generic name: tocilizumab (genetical recombination)] for the treatment of COVID-19. Actemra is a humanized anti-human IL-6 receptor monoclonal antibody created by Chugai.

Please refer to the link below for details of the press release:

Roche's phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia

<https://www.roche.com/investors/updates/inv-update-2020-09-18.htm>

Trademarks used or mentioned in this release are protected by laws.

###